Hi-Clearance Inc., a leading provider of dialysis management and medical equipment, reported a steady revenue increase in 2023, with after-tax net income reaching NT$359 million, marking a 3.16% year-over-year growth. Earnings per share (EPS) stood at NT$8.08, the fourth-highest in the company's history, solidifying its position among the most profitable biotech firms.
Consistent Dividend Policy and Financial Performance
Continuing its commitment to shareholder returns, Hi-Clearance Inc.’s board of directors approved a cash dividend of NT$7 per share. Additionally, the company allocated NT$4.53 million for employee compensation and NT$13.6 million for board remuneration. Hi-Clearance Inc. has maintained a strong earnings record, with profits consistently surpassing half of its capital for over a decade. In 2022, amid the COVID-19 pandemic, the company achieved record-breaking revenue of NT$4.69 billion and an EPS of NT$9.06. In 2023, revenue rebounded to NT$4.073 billion, a 4.54% increase, with major revenue contributions from artificial kidneys and dialysis circuits (34.1%), erythropoietin and dialysis fluids (30.4%), and other medical supplies (23.9%). Operating income reached NT$426 million, with net income attributable to shareholders at NT$359 million.
Diversification and Expansion Strategy
Founded in 1989, Hi-Clearance Inc. initially specialized in distributing TORAY hemodialysis products from Japan. Since 1996, the company has diversified its portfolio across multiple medical fields, including nephrology, cardiology, radiology, plastic surgery, dentistry, respiratory care, metabolic medicine, critical care, and long-term home care. Beyond product distribution, Hi-Clearance Inc. has vertically integrated its operations by managing dialysis centers, investing in home healthcare services, and expanding upstream into medical device manufacturing.
Key Growth Drivers and Future Outlook
Hi-Clearance Inc.’s 2023 performance was bolstered by increased hospital procurement of high-value orthopedic surgical navigation systems, in addition to stable demand for traditional hemodialysis consumables. Industry analysts attribute the company’s continued growth trajectory to the rising global dialysis population, as well as its strategic expansion into dental, cardiovascular, hemodialysis, and neurovascular medical device markets. Moreover, its investments in respiratory therapy and sleep medicine further enhance its market footprint. Looking ahead, Hi-Clearance Inc.’s revenue growth momentum is expected to extend into 2025, supported by its diversified portfolio and strategic investments in high-demand medical sectors.
Resource:業績穩定成長 杏昌去年EPS達8.08元
